Published online by Cambridge University Press: 29 July 2019
To report from the Scientific Development and Capacity Building Committee of Health Technology Assessment International (HTAi) on activities that are being undertaken within HTAi regarding the promotion of scientific rigor in the field of health technology assessment (HTA).
Retrieval of definitions of HTA that the SDCB committee considered reflective of the current practice of HTA, followed by a narrative synthesis of the core components of HTA.
Several definitions of HTA have been provided, all sharing the notion that HTA is the formal, systematic, and transparent inquiry into the meaning and value, broadly defined, of health technologies, when used in specific patient populations.
Many frameworks and tools have been developed for assessing the quality of specific tasks that may be conducted in the context of HTA. Collating such frameworks and tools is likely to be helpful in developing standards and in providing guidance as to how the scientific quality of HTA may be secured. Two current trends in HTA were noted: a stronger health systems focus, and the need to involve stakeholders throughout the HTA process. A wider systems’ perspective requires that plausible alternative scenarios are being developed, and wide consultation of various stakeholders is a prerequisite to the development of such scenarios with data from various sources.
Current trends in HTA will lead to different demands on the HTA expert. The task of this emerging policy professional would be not just to provide technical information for problem-solving, but also to combine it with a new function of facilitating public deliberation and learning.
This study is presented on behalf of the HTAi Scientific Development and Capacity Building (SDCB) committee: Ken Bond, Institute of Health Economics, Canada; Yingyao Chen, Key Lab of HTA, Ministry of Health, China; Sebastian Garcia Marti, Institute for Clinical Effectiveness and Health Policy, Argentina; Janet Martin, Schulich School of Medicine and Dentistry, Western University, Canada; Wija Oortwijn, Radboud University Medical Centre, the Netherlands; Andrés Pichon Riviere, Institute for Clinical Effectiveness and Health Policy, Argentina; Franz Pichler, Eli Lilly, Australia; Anna Scott, University of Sydney, Australia; Yue Xiao, China National Health Development Research Center, Division of Policy Evaluation and HTA, China. Financial Support: N/A. Ethics Committee Approval: N/A.